| abstract |
FIELD: medicine.SUBSTANCE: invention refers to treating cancer forms caused by a deregulated human epidermal growth factor receptor. TKI tyrosine kinase resistance therapeutic composition contains TKI and recombinant protein containing polypeptide containing full-length epidermal growth factor (EGF) or its part, an immunogenic polypeptide containing a cholera toxin B (CTB) polypeptide, and a linker, wherein the polypeptide is separated from the immunogenic polypeptide by a linker.EFFECT: invention provides treating cancer in individuals who have developed resistance or who do not respond to therapy with a TKI inhibitor.12 cl, 54 dwg, 9 tbl, 3 ex |